Across our channels, we regularly publish and engage in discussions about industry trends, changing regulations, and emerging technologies in clinical trials. This page hosts a selection of key articles and news.
On November 7th, Triall will host a live webinar on emerging technologies in clinical trials together with its partner Crucial Data Solutions.
Triall is now a member of the Mayo Clinic Innovation Exchange, a platform that unites entrepreneurs, startups, and Mayo Clinic experts to bring breakthrough innovations to market.
Triall featured in Forbes Magazine with a spotlight article on our platform and blockchain-enabled vision for clinical research.
Triall's recent collaboration with Mayo Clinic has been covered by Healthcare IT News in an article written by senior editor Andrea Fox.
Triall has entered into collaboration with researchers at the Mayo Clinic who will onboard Triall's blockchain-integrated eClinical platform into a multi-center pulmonary arterial hypertension trial.
Triall is now an official member of the Dutch Blockchain Coalition, a cooperative association of governmental bodies, centres of expertise, and commercial entities.
According to Science Magazine, several hallmark scientific papers on the origin of Alzheimer’s show clear signs of image tampering.
After many decades of product-centric research, industry stakeholders are now looking to reshape the patient's role from research subject into informed collaborator.
In our new 'Beyond the hype' article series we explain the ins and outs of emerging technologies and trends such as blockchain, decentralisation, and tokenisation.
Triall has partnered with Crucial Data Solutions, a leading eClinical solution provider whose software has been used in over 7,500 clinical trials.
Clinical trials are becoming increasingly digital, data-driven, and decentralised. What are some of the key emerging trends driving this shift?
The Triall Newsletter provides a concise overview of product innovation updates, upcoming events, and anything else Triall-related.